Symbols / PHIO $1.22 +0.83%
PHIO Chart
About
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.47M |
| Enterprise Value | -6.97M | Income | -8.70M | Sales | — |
| Book/sh | 1.73 | Cash/sh | 1.81 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -1.97 | PEG | — |
| P/S | — | P/B | 0.70 | P/C | — |
| EV/EBITDA | 0.76 | EV/Sales | — | Quick Ratio | 15.70 |
| Current Ratio | 16.03 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.15 | EPS next Y | -0.62 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 16:00 | ROA | -42.33% |
| ROE | -69.95% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 10.76M |
| Shs Float | 11.54M | Short Float | 21.78% | Short Ratio | 0.25 |
| Short Interest | — | 52W High | 4.19 | 52W Low | 0.81 |
| Beta | 0.91 | Avg Volume | 3.95M | Volume | 179.64K |
| Target Price | $14.00 | Recom | Strong_buy | Prev Close | $1.21 |
| Price | $1.22 | Change | 0.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.00
Mean price target
2. Current target
$1.23
Latest analyst target
3. DCF / Fair value
$-8.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.23
Low
$14.00
High
$14.00
Mean
$14.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-04-08 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-02-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
- Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan ue, 10 Mar 2026 11
- $PHIO stock is down 23% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Feb 2026 08
- Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - Yahoo Finance hu, 05 Mar 2026 21
- How Phio Pharmaceuticals Corp. stock compares to industry benchmarks - Buy Signal & High Accuracy Trade Signal Alerts - Naître et grandir Sat, 07 Mar 2026 13
- Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds - TMX Newsfile Mon, 03 Nov 2025 08
- Phio Pharmaceuticals Stock Falls 5% Amid Financing And Clinical Updates - Nasdaq Mon, 03 Nov 2025 08
- Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan hu, 05 Mar 2026 12
- Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm Wed, 04 Mar 2026 00
- $PHIO stock is down 14% today. Here's what we see in our data. - Quiver Quantitative Mon, 08 Dec 2025 08
- Top PH-762 skin cancer dose triggers 85% tumor response in Phio trial - Stock Titan ue, 10 Feb 2026 08
- Phio reshapes leadership as PH-762 cancer drug nears key tests - Stock Titan hu, 19 Feb 2026 08
- $PHIO stock is up 48% today. Here's what we see in our data. - Quiver Quantitative ue, 10 Feb 2026 08
- Phio Pharma (NASDAQ: PHIO) named Immunomodulatory Solution of the Year for PH-762 - Stock Titan Fri, 07 Nov 2025 08
- Phio Pharma (NASDAQ: PHIO) to present Phase 1b PH-762 skin cancer results at SITC - Stock Titan Fri, 07 Nov 2025 08
- Phio Pharmaceuticals (NASDAQ: PHIO) Reports PH-762 Data With 6 Complete Responses - Stock Titan ue, 25 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 120000 | — | — | Stock Award(Grant) at price 0.00 per share. | BITTERMAN ROBERT J | Chief Executive Officer | — | 2026-02-05 00:00:00 | D |
| 1 | 18500 | — | — | Stock Award(Grant) at price 0.00 per share. | BRADFORD PATRICIA A | Director | — | 2026-02-05 00:00:00 | D |
| 2 | 16600 | — | — | Stock Award(Grant) at price 0.00 per share. | LOCKSHIN CURTIS | Director | — | 2026-02-05 00:00:00 | D |
| 3 | 23800 | — | — | Stock Award(Grant) at price 0.00 per share. | DEMING DAVID H | Director | — | 2026-02-05 00:00:00 | D |
| 4 | 16600 | — | — | Stock Award(Grant) at price 0.00 per share. | FREEMAN JONATHAN E PH.D. | Director | — | 2026-02-05 00:00:00 | D |
| 5 | 47000 | — | — | Stock Award(Grant) at price 0.00 per share. | CARSON LISA CABOTT | Chief Financial Officer | — | 2026-02-05 00:00:00 | D |
| 6 | 5000 | 5150 | — | Purchase at price 1.03 per share. | BITTERMAN ROBERT J | Chief Executive Officer | — | 2025-12-31 00:00:00 | D |
| 7 | 5000 | 5100 | — | Purchase at price 1.02 per share. | BITTERMAN ROBERT J | Chief Executive Officer | — | 2025-12-23 00:00:00 | D |
| 8 | 5000 | 5700 | — | Purchase at price 1.14 per share. | BITTERMAN ROBERT J | Chief Executive Officer | — | 2025-11-21 00:00:00 | D |
| 9 | 5000 | 6350 | — | Purchase at price 1.27 per share. | BITTERMAN ROBERT J | Chief Executive Officer | — | 2025-11-18 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -7.35M | -10.39M | -11.27M | -13.32M |
| TotalUnusualItems | 0.00 | -126.00K | 0.00 | 233.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -126.00K | 0.00 | 233.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.15M | -10.83M | -11.48M | -13.29M |
| ReconciledDepreciation | 35.00K | 184.00K | 193.00K | 192.00K |
| EBITDA | -7.35M | -10.51M | -11.27M | -13.32M |
| EBIT | -7.39M | -10.70M | -11.46M | -13.51M |
| NetInterestIncome | 231.00K | -8.00K | -9.00K | |
| NormalizedIncome | -7.15M | -10.70M | -11.48M | -13.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.15M | -10.83M | -11.48M | -13.29M |
| TotalExpenses | 7.39M | 10.70M | 11.46M | 13.51M |
| TotalOperatingIncomeAsReported | -7.39M | -10.82M | -11.46M | -13.51M |
| DilutedAverageShares | 787.47K | 231.51K | 126.33K | 118.80K |
| BasicAverageShares | 787.47K | 231.51K | 126.33K | 118.80K |
| DilutedEPS | -9.08 | -46.76 | -90.86 | -112.32 |
| BasicEPS | -9.08 | -46.76 | -90.86 | -112.32 |
| DilutedNIAvailtoComStockholders | -7.15M | -10.83M | -11.48M | -13.29M |
| NetIncomeCommonStockholders | -7.15M | -10.83M | -11.48M | -13.29M |
| NetIncome | -7.15M | -10.83M | -11.48M | -13.29M |
| NetIncomeIncludingNoncontrollingInterests | -7.15M | -10.83M | -11.48M | -13.29M |
| NetIncomeContinuousOperations | -7.15M | -10.83M | -11.48M | -13.29M |
| TaxProvision | 0.00 | 0.00 | ||
| PretaxIncome | -7.15M | -10.83M | -11.48M | -13.29M |
| OtherIncomeExpense | 6.00K | -120.00K | -18.00K | 224.00K |
| OtherNonOperatingIncomeExpenses | 6.00K | 6.00K | -18.00K | 224.00K |
| SpecialIncomeCharges | 0.00 | -126.00K | 0.00 | 233.00K |
| OtherSpecialCharges | -233.00K | |||
| ImpairmentOfCapitalAssets | 0.00 | 126.00K | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 231.00K | -8.00K | -9.00K | |
| TotalOtherFinanceCost | -231.00K | 8.00K | 9.00K | |
| OperatingIncome | -7.39M | -10.70M | -11.46M | -13.51M |
| OperatingExpense | 7.39M | 10.70M | 11.46M | 13.51M |
| ResearchAndDevelopment | 3.64M | 6.33M | 7.01M | 8.89M |
| SellingGeneralAndAdministration | 3.74M | 4.37M | 4.45M | 4.62M |
| GeneralAndAdministrativeExpense | 3.74M | 4.37M | 4.45M | 4.62M |
| OtherGandA | 3.74M | 4.37M | 4.45M | 4.62M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.73M | 416.37K | 126.56K | 125.32K |
| ShareIssued | 1.73M | 416.37K | 126.56K | 125.32K |
| TotalDebt | 0.00 | 35.00K | 170.00K | 295.00K |
| TangibleBookValue | 4.72M | 7.73M | 10.84M | 21.93M |
| InvestedCapital | 4.72M | 7.73M | 10.84M | 21.93M |
| WorkingCapital | 4.72M | 7.69M | 10.51M | 21.66M |
| NetTangibleAssets | 4.72M | 7.73M | 10.84M | 21.93M |
| CapitalLeaseObligations | 0.00 | 35.00K | 170.00K | 295.00K |
| CommonStockEquity | 4.72M | 7.73M | 10.84M | 21.93M |
| TotalCapitalization | 4.72M | 7.73M | 10.84M | 21.93M |
| TotalEquityGrossMinorityInterest | 4.72M | 7.73M | 10.84M | 21.93M |
| StockholdersEquity | 4.72M | 7.73M | 10.84M | 21.93M |
| RetainedEarnings | -146.36M | -139.21M | -128.38M | -116.90M |
| AdditionalPaidInCapital | 151.08M | 146.94M | 139.22M | 138.83M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 1.01M | 1.63M | 1.98M | 3.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 37.00K | 170.00K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 2.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 35.00K | 170.00K | |
| LongTermCapitalLeaseObligation | 0.00 | 35.00K | 170.00K | |
| CurrentLiabilities | 1.01M | 1.63M | 1.94M | 3.07M |
| OtherCurrentLiabilities | 19.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 35.00K | 135.00K | 125.00K | |
| CurrentCapitalLeaseObligation | 0.00 | 35.00K | 135.00K | 125.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 31.00K | 222.00K | 408.00K | 572.00K |
| PayablesAndAccruedExpenses | 984.00K | 1.38M | 1.40M | 2.37M |
| CurrentAccruedExpenses | 731.00K | 720.00K | 617.00K | 2.09M |
| Payables | 253.00K | 657.00K | 779.00K | 283.00K |
| AccountsPayable | 253.00K | 657.00K | 779.00K | 283.00K |
| TotalAssets | 5.74M | 9.36M | 12.81M | 25.17M |
| TotalNonCurrentAssets | 2.00K | 42.00K | 368.00K | 443.00K |
| OtherNonCurrentAssets | 3.00K | 24.00K | 27.00K | |
| NetPPE | 2.00K | 39.00K | 344.00K | 416.00K |
| AccumulatedDepreciation | -306.00K | -1.14M | -1.18M | -1.10M |
| GrossPPE | 308.00K | 1.18M | 1.52M | 1.52M |
| Leases | 0.00 | 46.00K | 46.00K | 46.00K |
| OtherProperties | 33.00K | 161.00K | 283.00K | |
| MachineryFurnitureEquipment | 308.00K | 1.10M | 1.31M | 1.19M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.74M | 9.32M | 12.45M | 24.73M |
| OtherCurrentAssets | 354.00K | 832.00K | 615.00K | 620.00K |
| RestrictedCash | 0.00 | 50.00K | 50.00K | |
| PrepaidAssets | 620.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 5.38M | 8.49M | 11.78M | 24.06M |
| CashAndCashEquivalents | 5.38M | 8.49M | 11.78M | 24.06M |
| CashFinancial | 5.38M | 8.49M | 11.78M | 24.06M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.11M | -10.75M | -12.25M | -11.91M |
| RepurchaseOfCapitalStock | -1.00K | -13.00K | 0.00 | |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 4.00M | 7.45M | 2.00K | 19.58M |
| CapitalExpenditure | -1.00K | -5.00K | -121.00K | -51.00K |
| InterestPaidSupplementalData | 13.00K | 11.00K | 8.00K | |
| EndCashPosition | 5.38M | 8.49M | 11.83M | 24.11M |
| BeginningCashPosition | 8.49M | 11.83M | 24.11M | 14.29M |
| ChangesInCash | -3.11M | -3.34M | -12.28M | 9.81M |
| FinancingCashFlow | 4.00M | 7.41M | -26.00K | 21.72M |
| CashFlowFromContinuingFinancingActivities | 4.00M | 7.41M | -26.00K | 21.72M |
| NetOtherFinancingCharges | -5.00K | -26.00K | -28.00K | -1.00K |
| ProceedsFromStockOptionExercised | 0.00 | 2.15M | ||
| NetPreferredStockIssuance | 0.00 | -2.00K | 2.00K | 0.00 |
| PreferredStockPayments | 0.00 | -2.00K | 0.00 | |
| PreferredStockIssuance | 0.00 | 2.00K | 0.00 | |
| NetCommonStockIssuance | 4.00M | 7.44M | 0.00 | 19.58M |
| CommonStockPayments | -1.00K | -11.00K | 0.00 | |
| CommonStockIssuance | 4.00M | 7.45M | 0.00 | 19.58M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 8.00K | -5.00K | -121.00K | -51.00K |
| CashFlowFromContinuingInvestingActivities | 8.00K | -5.00K | -121.00K | -51.00K |
| NetOtherInvestingChanges | 9.00K | |||
| NetPPEPurchaseAndSale | -1.00K | -5.00K | -121.00K | -51.00K |
| PurchaseOfPPE | -1.00K | -5.00K | -121.00K | -51.00K |
| OperatingCashFlow | -7.11M | -10.75M | -12.13M | -11.86M |
| CashFlowFromContinuingOperatingActivities | -7.11M | -10.75M | -12.13M | -11.86M |
| ChangeInWorkingCapital | -138.00K | -536.00K | -1.26M | 990.00K |
| ChangeInOtherCurrentLiabilities | -35.00K | -135.00K | -125.00K | -116.00K |
| ChangeInPayablesAndAccruedExpense | -584.00K | -205.00K | -1.14M | 865.00K |
| ChangeInAccruedExpense | -180.00K | -83.00K | -1.64M | 1.31M |
| ChangeInPayable | -404.00K | -122.00K | 496.00K | -445.00K |
| ChangeInAccountPayable | -404.00K | -122.00K | 496.00K | -445.00K |
| ChangeInPrepaidAssets | 481.00K | -196.00K | 8.00K | 241.00K |
| OtherNonCashItems | 117.00K | |||
| StockBasedCompensation | 147.00K | 303.00K | 414.00K | 480.00K |
| AssetImpairmentCharge | 0.00 | 126.00K | 0.00 | |
| DepreciationAmortizationDepletion | 35.00K | 184.00K | 193.00K | 192.00K |
| DepreciationAndAmortization | 35.00K | 184.00K | 193.00K | 192.00K |
| Depreciation | 35.00K | 184.00K | 193.00K | 192.00K |
| OperatingGainsLosses | -6.00K | -233.00K | ||
| GainLossOnSaleOfPPE | -6.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -7.15M | -10.83M | -11.48M | -13.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PHIO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|